$0.567500
-0.03-4.62%
At Close: -
$0.565000
-0.0025-0.44%
After Hours: 6:01 PM EDT
15 minutes delayed
Comments
Loading...
Forte Biosciences
FBRXNASDAQ
Forte Biosciences (NASDAQ:FBRX) Stock, Analyst Ratings, Price Targets, Forecasts
Forte Biosciences Inc has a consensus price target of $3.31 based on the ratings of 5 analysts. The high is $4 issued by Brookline Capital on May 30, 2024. The low is $2.75 issued by Ladenburg Thalmann on April 8, 2024. The 3 most-recent analyst ratings were released by Brookline Capital, Ladenburg Thalmann, and Chardan Capital on May 30, 2024, April 8, 2024, and September 20, 2021, respectively. With an average price target of $3.42 between Brookline Capital, Ladenburg Thalmann, and Chardan Capital, there's an implied 504.72% upside for Forte Biosciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Brookline Capital
Ladenburg Thalmann
Chardan Capital
B. Riley Securities
1calculated from analyst ratings
Analyst Ratings for Forte Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/30/2024 | Buy Now | 607.96% | Brookline Capital | Kumaraguru Raja | → $4 | Initiates | → Buy | Get Alert |
| 04/08/2024 | Buy Now | 386.73% | Ladenburg Thalmann | Michael Higgins | → $2.75 | Upgrade | Neutral → Buy | Get Alert |
| 09/20/2021 | Buy Now | 519.47% | Chardan Capital | Keay Nakae | — | Upgrade | Sell → Neutral | Get Alert |
| 09/03/2021 | Buy Now | — | Brookline Capital | Kumaraguru Raja | — | Downgrade | Buy → Hold | Get Alert |
| 09/03/2021 | Buy Now | 607.96% | Chardan Capital | Keay Nakae | — | Downgrade | Buy → Sell | Get Alert |
| 09/03/2021 | Buy Now | — | Ladenburg Thalmann | Michael Higgins | — | Downgrade | Buy → Neutral | Get Alert |
| 09/03/2021 | Buy Now | 430.97% | B. Riley Securities | Kalpit Patel | — | Downgrade | Buy → Neutral | Get Alert |
| 09/03/2021 | Buy Now | — | Truist Securities | Nicole Germino | — | Downgrade | Buy → Hold | Get Alert |
FAQ
What is the target price for Forte Biosciences (FBRX) stock?
The latest price target for Forte Biosciences (NASDAQ:FBRX) was reported by Brookline Capital on May 30, 2024. The analyst firm set a price target for $4.00 expecting FBRX to rise to within 12 months (a possible 607.96% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Forte Biosciences (FBRX)?
The latest analyst rating for Forte Biosciences (NASDAQ:FBRX) was provided by Brookline Capital, and Forte Biosciences initiated their buy rating.
When was the last upgrade for Forte Biosciences (FBRX)?
The last upgrade for Forte Biosciences Inc happened on April 8, 2024 when Ladenburg Thalmann raised their price target to $2.75. Ladenburg Thalmann previously had a neutral for Forte Biosciences Inc.
When was the last downgrade for Forte Biosciences (FBRX)?
The last downgrade for Forte Biosciences Inc happened on September 3, 2021 when Brookline Capital changed their price target from N/A to N/A for Forte Biosciences Inc.
When is the next analyst rating going to be posted or updated for Forte Biosciences (FBRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Forte Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Forte Biosciences was filed on May 30, 2024 so you should expect the next rating to be made available sometime around May 30, 2025.
Is the Analyst Rating Forte Biosciences (FBRX) correct?
While ratings are subjective and will change, the latest Forte Biosciences (FBRX) rating was a initiated with a price target of $0.00 to $4.00. The current price Forte Biosciences (FBRX) is trading at is $0.56, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.